Risk of osteoporotic fractures in new users of denosumab compared with new users of alendronate: A Danish populationbased cohort study

Ítems similars

• Comparison of risk of osteoporotic fracture in Denosumab vs Alendronate treatment within 3 years of initiation
  per: Pedersen, AB, et al.
  Publicat: (2019)
• Reduction in fracture rates with Denosumab compared to Alendronate in treatment naïve patients: a propensity-matched ‘real world’ cohort and instrumental variable analysis.
  per: Khalid, S, et al.
  Publicat: (2017)
• Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including over 60,000 alendronate users.
  per: Eiken, P, et al.
  Publicat: (2017)
• Use of Thiazolidinediones and Risk of Osteoporotic Fracture: The Danish National Databases
  per: Bazelier, M, et al.
  Publicat: (2011)
• Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study
  per: Prieto Alhambra, D, et al.
  Publicat: (2016)